Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06249555 · ClinicalTrials.gov registry record

VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

A clinical trial of Crohn's Disease, sponsored by Alimentiv.

Recruiting
Registry status
300
Enrollment target
20
Study locations

NCT06249555 is a study of Crohn's Disease that is actively recruiting participants, run by Alimentiv. The registered enrollment target is 300 participants, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06249555, a study of Crohn's Disease, is actively recruiting participants, sponsored by Alimentiv.

RECRUITING
Registry status
300 participants
Enrollment target
20
Study locations

Study Summary

The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sleep disturbance, physical function, and ability to participate in social roles and activities); other PRO measures will also be assessed.

Conditions Studied

Crohn's Disease

Interventions

  • DRUG Vedolizumab (VDZ)
  • DRUG Ustekinumab (UST)
  • DRUG Risankizumab (RISA)
  • DRUG Guselkumab (GUS)
  • DRUG Mirikizumab (MIR)

Study Locations (20)

Ontario

  • GNRR Digestive Clinics and Research Center - Brampton
  • London Health Sciences Centre - London
  • Alimentiv - London
  • West GTA Research Inc. - Mississauga
  • Rajbir Rai Medicine Professional Corporation - Oakville
  • ABP Research Services Corp. - Oakville

Texas

  • GI Alliance Research Fort Worth - Fort Worth
  • GI Alliance Research Mansfield - Mansfield

Arizona

  • GI Alliance - Sun City - Sun City

Florida

  • Digestive and Liver Center of Florida - Kissimmee

Illinois

  • Northwestern University - Evanston

Iowa

  • University of Iowa - Iowa City

Louisiana

  • University Medical Center New Orleans - New Orleans

Massachusetts

  • Brigham and Women's Hospital - Chestnut Hill

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-03-20
Est. Completion 2026-12

Sponsor

Alimentiv

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06249555

The ClinicalTrials.gov registry entry for NCT06249555 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,412-participant average among 104 other Crohn's Disease trials with a reported enrollment target (88% lower). The listed sponsor is Alimentiv, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 5 interventions - of which Vedolizumab (VDZ) is the first listed.

NCT06249555 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Ontario, Texas, Arizona.

Frequently Asked Questions

What is clinical trial NCT06249555 about?

NCT06249555 is a clinical study titled "VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study". The primary aim of this study is to explore the time course of response to Vedolizumab in participants with CD as measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference-short form (SF), as well as other PROMIS domain SFs (fatigue, anxiety, depression, sle...

What is the current status of trial NCT06249555?

This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2024-03-20. Estimated completion is 2026-12.

What conditions does trial NCT06249555 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT06249555?

The interventions under investigation include: Vedolizumab (VDZ) (DRUG), Ustekinumab (UST) (DRUG), Risankizumab (RISA) (DRUG), Guselkumab (GUS) (DRUG), Mirikizumab (MIR) (DRUG).

Who is sponsoring clinical trial NCT06249555?

This trial is sponsored by Alimentiv, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06249555 being conducted?

This trial has 20 study locations across Arizona, Florida, Illinois, Iowa, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.